<DOC>
	<DOCNO>NCT02566031</DOCNO>
	<brief_summary>To demonstrate superiority QVA149 ( 110/50 μg ) daily compare tiotropium 18 μg daily term trough force expiratory volume 1 second ( FEV1 ) ( mean 45 min 15 min pre-dose ) follow 12 week treatment mild moderate symptomatic COPD patient</brief_summary>
	<brief_title>A Randomized , Multicenter , Open-label , Parallel-group , 12-week Study Assess Efficacy Safety Switching From Tiotropium QVA149 ( Indacaterol Maleate/Glycopyrronium Bromide ) Symptomatic Mild Moderate COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Confirmed diagnosis COPD postbronchodilator FEV1 ≥ 50 % predict normal value postbronchodilator FEV1/FVC &lt; 0.7 ( COPD Grade 1 2 severity airflow limitation ( GOLD 2015 ) Patients CAT score ≥ 10 Visit 0 Visit 1 . Patients tiotropium monotherapy past 3 month . 0 1 COPD exacerbation previous 12 month ( lead hospital admission ) . Treatment inhaled corticosteroid ( ICS ) 3 month prior Visit 1 . COPD exacerbation Visit 0 1 . Patients concomitant pulmonary disease Patients history respiratory infection within 4 week prior Visit 0 . Prior current diagnosis asthma . Presence contraindication , warning , precaution , hypersensitivity LABA LAMA Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>open-label</keyword>
	<keyword>QVA149</keyword>
	<keyword>symptomatic</keyword>
	<keyword>tiotropium</keyword>
</DOC>